Alnara Pharmaceuticals, Inc. (Alnara) is dedicated to developing and commercializing novel protein therapeutics for the treatment of metabolic diseases. The company’s innovative approach focuses on designing effective protein therapies that can be orally delivered directly to the gastrointestinal tract without being absorbed into the bloodstream. Alnara’s lead product is liprotamase, a novel, non-porcine pancreatic enzyme replacement therapy, which has completed Phase 3 clinical development in collaboration with the Cystic Fibrosis Foundation Therapeutics, Inc. and is currently under review by the FDA. Alnara was co-founded in 2008 by Alexey Margolin, Rich Aldrich and Christoph Westphal and sold to Eli Lilly in 2010 for $180M upfront and an additional $200M in potential earnouts. For more information, please visit the company’s website www.alnara.com.
Verastem, Inc. (Verastem) (NASDAQ: VSTM) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. For more information, please visit the company’s website at www.verastem.com.
OvaScience, Inc. (OvaScience) (NASDAQ: OVAS) is applying innovative science to improve the quality of eggs and increase the success of in vitro fertilization (IVF). OvaScience’s patented technology, exclusively licensed from Harvard Medical School and Massachusetts General Hospital, enables the use of a women’s own cellular energy to improve egg quality. OvaScience was co-founded by Richard Aldrich, Michelle Dipp, M.D., Ph.D., and Christoph Westphal M.D., Ph.D., of Longwood Fund, along with fertility expert and Harvard Medical School Professor Jonathan Tilly, Ph.D. of Massachusetts General Hospital, and aging expert and Harvard Medical School Professor David Sinclair, Ph.D. For more information, please visit the company’s website at www.ovascience.com.
IlluminOss Medical is a privately held medical device company dedicated to bringing minimally invasive solutions for the stabilization and treatment of bone fractures to market. With an aging population contributing to the growing number of fracture incidences, there is a compelling need for a method of fracture repair to successfully mend osteoporotic bone. The IlluminOss Photodynamic Bone Stabilization System utilizes a photodynamic (light-curable) polymer system intended to modernize the traditional methods of bone fixation, which still use metal rods and screws and are not effective for osteoporotic patients. For more information, please visit the company’s website at www.illuminoss.com/us.
PTC Therapeutics, Inc. (PTC) (NASDAQ: PTCT) is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC has assembled proprietary technologies and extensive knowledge of post-transcriptional control processes that it applies in its drug discovery and development activities. PTC's current pipeline of clinical and preclinical product candidates addresses multiple indications, including genetic disorders, oncology, and infectious diseases. For more information, please visit the company’s website www.ptcbio.com.
Mitokyne, Inc. (Mitokyne) is a biopharmaceutical company focused on mitochondria-related drug discovery and development. The company is utilizing its innovative screening platform to identify and develop novel drugs that improve mitochondria function and provide treatments for genetic, metabolic and neurodegenerative disorders as well as diseases and conditions of aging. Mitokyne’s mission is to become the leader in developing drugs that can treat a wide range of serious diseases by modulating mitochondrial function. Mitokyne’s proprietary systems biology platform will be used to identify targets and biomarkers related to mitochondrial function and optimize the pipeline of differentiated drug candidates. The emerging biological understanding of mitochondria, along with new tools and assays available to better elucidate mitochondrial function and processes, will enable the identification of breakthrough treatments for patients suffering from mitochondria-related diseases and improve their quality of life. Mitokyne’s scientific founders and advisors include world-renowned leaders in biology and mitochondrial function.
Calithera Biosciences, Inc. (Calithera) is discovering and developing novel small molecule oncology therapeutics that inhibit pathways critical to tumor growth and survival. The Calithera team has the experience and the ability needed to discover novel therapeutics and advance these discoveries through clinical development. The company is applying this expertise to build a pipeline of anti-cancer compounds that are distinct from other oncology therapeutics. Calithera’s lead clinical candidate, CB-839, blocks glutaminase, an enzyme critical to tumor metabolism, and is poised to enter Phase 1 clinical testing. Calithera Biosciences is a privately held company located in South San Francisco, CA. For more information, please visit the company’s website www.calithera.com.